84782
document
Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy . Silicone Study Report 5 . The Silicone Study Group . In the Silicone Study , 117 of 404 eyes ( 29 % ) with severe proliferative vitreoretinopathy ( > or = C-3 , full-thickness retinal folds in three or more quadrants ) enrolled in the study were treated with vitrectomy , underwent a relaxing retinotomy , and were randomly assigned to treatment with long-acting gas or silicone oil . Forty-six eyes ( 20 % ) had undergone no previous vitrectomy ( group 1 ) ; 71 eyes ( 42 % ) had undergone previous vitrectomy ( group 2 ) with intraocular gas tamponade ( P < .001 ) . Group 1 eyes not undergoing retinotomy had better anatomic ( six months ) and visual ( six and 24 months ) outcomes and less hypotony ( six months ) than eyes that did regardless of tamponade ( P < .05 ) . For eyes undergoing retinotomy , silicone oil decreased the likelihood of hypotony ( six months , P < .05 ) . These differences were not found in group 2 eyes . We conclude that eyes undergoing a vitreous operation for the first time for the treatment of proliferative vitreoretinopathy can in most instances be successfully treated by conventional techniques without the need for relaxing retinotomy . Retinotomy may be required more often in patients undergoing repeat vitreous surgery for proliferative vitreoretinopathy , in which case both silicone oil and long-acting perflouropropane gas appear to be equally effective .
84783
Intervention_Physical
Relaxing retinotomy with silicone oil or long-acting gas
84784
Intervention_Pharmacological
vitrectomy
84785
Intervention_Surgical
relaxing retinotomy
84786
Intervention_Pharmacological
treatment with long-acting gas or silicone oil
84787
Intervention_Pharmacological
perflouropropane
84788
Outcome_Physical
better anatomic ( six months )
84789
Outcome_Physical
visual ( six and 24 months ) outcomes
84790
Outcome_Physical
hypotony
84791
Outcome_Physical
hypotony
84792
Outcome_Physical
proliferative vitreoretinopathy
84793
Outcome_Other
equally effective
84794
Participant_Condition
proliferative vitreoretinopathy
84795
Participant_Sample-size
117
84796
Participant_Sample-size
404
84797
Participant_Condition
proliferative vitreoretinopathy
84798
Participant_Sample-size
Forty-six